EOS INC. is a resourceful service provider that integrates leading biotechnology and products from around the world. We are committed to developing products in different fields around the world to provide consumers with new experiences and extra added value in purchasing products and consuming and adding value to them.
On December 8, 2023, Eos Inc. and ZHONGKEZHONGLUAN (Guangdong) Holdings (Group) Limited hosted a signing ceremony in Shenzhen, China, opening a new era of cooperation between capital economy and regenerative medicine.
Since its establishment in 2022, ZHONGKEZHONGLUAN has been committed to the research and development and transformation of cutting-edge biomedical technologies. With more than 3,700 world-leading core technologies, ZHONGKEZHONGLUAN is at the forefront of regenerative medicine and biotechnology. Relying on the Group’s strong technological strength, ZHONGKEZHONGLUAN biotechnology has shown great potential for development.
The collaboration will fully combine the resource strengths of both parties in the fields of biotechnology, regenerative medicine and capital economy to jointly empower each other’s business development and realize a win-win situation. Both parties will work closely together in the future to utilize innovative business models and biotechnology to achieve their strategic development goals.
Both parties will fully utilize their respective advantages in technology, market and talents to jointly develop cooperation in industrial transformation and upgrading, etc. Both parties hope that through exchanges and cooperation, they will continue to enhance each other’s competitiveness and core strengths.
We believe that through the close cooperation between the two sides, new vitality will be injected into the human health business and regenerative medicine.
For more information on EOS, Inc. please visit the website: https://eosinc999.us/
Forward-Looking Statements: Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Risk factors that could cause actual results to differ materially from those projected in forward-looking statements include, but are not limited to, general business conditions, managing growth, and political and other business risks. All forward-looking statements are expressly qualified in their entirety by this paragraph and the risks and other factors detailed in EOS’ reports filed with the Securities and Exchange Commission. EOS INC. undertakes no duty to update these forward-looking statements.